Dow Jones received a payment from EQS/DGAP to publish this press release.
DGAP-Media / 2018-06-14 / 09:30
*MagForce AG Co-Sponsors the University Hospital of Münster's **Annual Brain
Cancer Patient Event *
*Berlin, Germany and Nevada, USA, June 14, 2018* - MagForce AG (Frankfurt,
Scale, XETRA: MF6,ISIN: DE000A0HGQF5), a leading medical device company in
the field of nanomedicine focused on oncology, is delighted to announce that
the Company will again co-sponsor an event for brain cancer patients and
their relatives held on the occasion of the 2018 World Brain Tumor Day. The
event will be hosted by the University Hospital of Münster's Brain Tumor
Center and will take place on June 16, 2018.
Under the slogan "Wieder unterwegs! Von der Klinik in die Welt (On the road
again! From the clinic into the world)" this year's event will feature
speeches from brain tumor patients reporting on their travels after
diagnosis. Sharing their experiences, both trying and beautiful, with others
affected by the disease, the 2018 event is dedicated to encouraging brain
tumor patients, and their loved ones, to overcome not only national borders
but also their own fears.
The event will take place at the Restaurant Bakenhof in Münster, Germany, on
Saturday, June 16, 2018, from 10am to 2pm CEST. MagForce will be available
for questions regarding its NanoTherm therapy for the treatment of brain
tumors and will be represented by an informational booth at the venue.
The University Hospital of Münster was the second medical center in Germany
to install a NanoActivator device, following the Charité University Hospital
in Berlin. Recently, the Team of Prof. Dr. med. Walter Stummer, Director of
the Neurosurgery Department at the University Hospital Münster and Chair of
the UKM Brain Tumor Centre, which has been treating brain tumor patients
with MagForce's NanoTherm Therapy since early 2015, reported their
experiences with NanoTherm therapy during a symposium entitled "Local
Therapies for Malignant Gliomas" at the 69th Annual Meeting of the German
Society of Neurosurgery, DGNC 2018. MagForce was pleased by the significant
interest in the symposium and NanoTherm therapy reflected by more than 120
attendees from the scientific and medical community. Increased attention
shown by a number of clinics and first-class neurosurgeons from other
European countries is especially valuable to MagForce, since the Comapny
continues to expand its commercialization to further European sites in order
to allow patients treatment with NanoTherm therapy in their home countries.
For further information regarding the program (German only) and
registration, please visit:
*https://www.ukm.de/index.php?id=vollstaendiger_artikel&tx_ttnews%5Btt_news%
5D=8525&cHash=cfd4bb300b5e61065b8608cd6b6b9e58 [1] *
*Role of NanoTherm Therapy in the Treatment of Brain Tumors*
NanoTherm therapy is an intratumoral thermotherapy which aims to help
patients with brain tumors. With NanoTherm therapy, the paramagnetic fluid
injected into a tumor is heated through a very fast alternating magnetic
field. Through the heat, tumor cells are either destroyed or sensitized for
additional therapies such as radiotherapy and/or chemotherapy; thus, the
efficacy of the additional therapies is improved.
MagForce AG has CE mark (European Certification) in Germany and in the EU 28
to treat brain tumors with NanoTherm therapy.
*About the World Brain Tumor Day*
This commemoration day was initialised by the Deutsche Hirntumorhilfe e.V.
(German Brain Tumor Association) in 2000. Because brain tumors occur rather
seldom in comparison to other cancers, they are little-noticed by the
public. With the aim of directing public attention to the situation of brain
tumor patients and appealing for solidarity with patients and their
dependants, the World Brain Tumor Day takes place every year on June 8th. It
is also a reminder directed at the responsible persons in the fields of
politics and economy to assume their social responsibility. Active support
of research and an increased interdisciplinary collaboration are the ways to
develop new therapies and improve the chances of healing. Until that, it is
essential to campaign together to advance the quality of life of patients,
to give hope and show solidarity - it is essential to send a signal.
*About MagForce AG and MagForce USA, Inc.*
MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange
(MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc.
is a leading medical device company in the field of nanomedicine focused on
oncology. The Group's proprietary NanoTherm(R) therapy enables the targeted
treatment of solid tumors through the intratumoral generation of heat via
activation of superparamagnetic nanoparticles.
NanoTherm(R), NanoPlan(R), and NanoActivator(R) are components of the
therapy and have received EU-wide regulatory approval as medical devices for
the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and
NanoActivator are trademarks of MagForce AG in selected countries.
*For more information, please visit: www.magforce.com [2]. *
*Get to know our Technology: video (You Tube) [3] *
_Disclaimer _
This release may contain forward-looking statements and information which
may be identified by formulations using terms such as "expects", "aims",
"anticipates", "intends", "plans", "believes", "seeks", "estimates" or
"will". Such forward-looking statements are based on our current
expectations and certain assumptions, which may be subject to a variety of
risks and uncertainties. The results actually achieved by MagForce AG may
substantially differ from these forward-looking statements. MagForce AG
assumes no obligation to update these forward-looking statements or to
correct them in case of developments, which differ from those, anticipated.
*Contact:*
Barbara von Frankenberg
Vice President
Communications & Investor Relations
T +49-30-308380-77
E-Mail: bfrankenberg@magforce.com [4]
End of Media Release
Issuer: MagForce AG
Key word(s): Health
2018-06-14 Dissemination of a Press Release, transmitted by DGAP - a service
of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: MagForce AG
Max-Planck-Straße 3
12489 Berlin
Germany
Phone: +49 (0)30 308 380 0
Fax: +49 (0)30 308 380 99
E-mail: info@magforce.com
Internet: www.magforce.com
ISIN: DE000A0HGQF5
WKN: A0HGQF
Indices: Scale 30
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt
(Scale), Stuttgart, Tradegate Exchange
End of News DGAP Media
695241 2018-06-14
1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=325547ffccb39ba54ed70b429b2eb2fc&application_id=695241&site_id=vwd&application_name=news
2: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=8c9fb96f72ca3bbe10dd7f041cbe6fa6&application_id=695241&site_id=vwd&application_name=news
3: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=fee20ce56f7c48d1562a60533ead43c9&application_id=695241&site_id=vwd&application_name=news
4: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=923963949e79c87737c86a672913a045&application_id=695241&site_id=vwd&application_name=news
(END) Dow Jones Newswires
June 14, 2018 03:29 ET (07:29 GMT)
